MENU
IDNA
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IDNA stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for IDNA with price predictions
Nov 10, 2026

Aroon Indicator for IDNA shows an upward move is likely

IDNA's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 199 similar instances where the Aroon Indicator showed a similar pattern. In 173 of the 199 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IDNA as a result. In 76 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 243 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where IDNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

IDNA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Merck & Co (NYSE:MRK), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-. The fund is non-diversified.

Market Cap

The average market capitalization across the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF is 32.58B. The market cap for tickers in the group ranges from 313.68M to 362.01B. MRK holds the highest valuation in this group at 362.01B. The lowest valued company is OCGN at 313.68M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was 0%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 45%. XNCR experienced the highest price growth at 29%, while JANX experienced the biggest fall at -32%.

Volume

The average weekly volume growth across all stocks in the iShares Genomics Immunology and Healthcare ETF (IDNA) ETF was 14%. For the same stocks of the ETF, the average monthly volume growth was -18% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 54
Price Growth Rating: 48
SMR Rating: 84
Profit Risk Rating: 81
Seasonality Score: 8 (-100 ... +100)
Aroon Indicator for IDNA shows an upward move is likely